drugset / Trial / NCT00911261

Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

NCT00911261

Phase 3 Completed 223 enrolled Endo USA Inc., a Keenova Therapeutics Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.

Timeline

Start
2003-08
Primary completion
2005-03
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymorphone Small molecule 5 mg
Subject Oxymorphone Small molecule 10 mg
Subject Oxymorphone Small molecule 20 mg
Subject Oxymorphone Small molecule 40 mg